GLP-1 Market
LLY $1145.85 ▼ -1.0% NVO $37.74 ▼ -0.4% PFE $28.20 ▼ -1.1% VKTX $31.18 ▼ -4.3% KLRA $11.04 ▼ -3.3% GPCR $29.70 ▼ -5.0% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Petrelintide

Company
Zealand Pharma
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for Petrelintide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07682818

    Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function

    Not yet reported Zealand Pharma 36 participants Est. completion 2027-04-12 3 sites Stand-alone
    Other conditions: Impaired Hepatic Function
    View official trial listing →
  • Completed NCT NCT06662539

    Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

    Not yet reported Zealand Pharma 493 participants Est. completion 2026-03-07 32 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06926842

    Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

    Not yet reported Zealand Pharma 221 participants Est. completion 2026-08-13 48 sites Stand-alone
    Type 2 diabetes Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT07076030

    Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

    Not yet reported Zealand Pharma 39 participants Est. completion 2025-11-25 1 site Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT07338214

    Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

    Not yet reported Zealand Pharma 48 participants Est. completion 2026-03-31 1 site
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07589686

    A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

    Not yet reported Hoffmann-La Roche 486 participants Est. completion 2028-01-31 Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07843472

    A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

    Not yet reported Hoffmann-La Roche 2500 participants Est. completion 2030-10-06 Stand-alone
    Cardiovascular disease Other conditions: Obesity or Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07843485

    A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 600 participants Est. completion 2029-01-19 Stand-alone
    Type 2 diabetes Other conditions: Obesity or Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07843498

    A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

    Not yet reported Hoffmann-La Roche 3900 participants Est. completion 2029-03-22 Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.